

Gina Mejía-a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6553865/publications.pdf>

Version: 2024-02-01

30
papers

796
citations

758635

12
h-index

525886

27
g-index

32
all docs

32
docs citations

32
times ranked

1642
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. <i>Lancet, The</i> , 2020, 395, 1705-1714.	6.3	347
2	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. <i>Biomedicines</i> , 2020, 8, 94.	1.4	57
3	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485.	1.2	51
4	Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 321-329.	1.2	39
5	Polymorphisms in <i>CYP1A2</i> , <i>CYP2C9</i> and <i>ABCB1</i> affect agomelatine pharmacokinetics. <i>Journal of Psychopharmacology</i> , 2019, 33, 522-531.	2.0	36
6	Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 2558-2570.e7.	1.1	31
7	First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 124-135.	2.3	25
8	Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 54.	1.0	19
9	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2051-2062.	1.1	19
10	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. <i>Journal of Personalized Medicine</i> , 2021, 11, 204.	1.1	19
11	Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. <i>Advances in Therapy</i> , 2021, 38, 1035-1054.	1.3	17
12	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020, 37, 3537-3550.	1.3	16
13	Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors: A Population-Based Study in Spain. <i>Frontiers in Pharmacology</i> , 2020, 11, 734.	1.6	12
14	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111087.	2.5	12
15	Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021, 60, 261-270.	1.6	12
16	PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3772.	1.0	12
17	Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. <i>Pharmacogenomics Journal</i> , 2020, 20, 235-245.	0.9	10
18	Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. <i>Human Psychopharmacology</i> , 2021, 36, 1-12.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. <i>Advances in Therapy</i> , 2022, 39, 1743-1753.	1.3	10
20	Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. <i>Pharmacogenomics</i> , 2020, 21, 663-675.	0.6	8
21	Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. <i>Pharmaceutics</i> , 2021, 13, 2036.	2.0	8
22	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceutics</i> , 2022, 15, 78.	1.7	8
23	Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573.	2.0	4
24	Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. <i>Frontiers in Pharmacology</i> , 2021, 12, 718281.	1.6	4
25	ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112083.	2.5	3
26	Patients' Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 270.	1.1	3
27	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. <i>BMJ Open</i> , 2020, 10, e037443.	0.8	2
28	Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. <i>Frontiers in Pharmacology</i> , 2021, 12, 660639.	1.6	1
29	Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. <i>Advances in Therapy</i> , 2021, 38, 4070-4081.	1.3	1
30	Efficacy and safety of preoperative preparation with Lugol's iodine solution in euthyroid patients with Graves' disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100806.	0.5	0